Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 9, 2025
Aya Gold & Silver Reports April Production as Zgounder Ramp Up Gains Momentum
GlobeNewswire
·
May 9, 2025
MONTREAL, May 09, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to report continued operational progress at its Zgounder Silver Mine, driven by a strong mine ramp up, exceptional mill …
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
GlobeNewswire
·
May 9, 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented …
Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting
GlobeNewswire
·
May 9, 2025
First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in line with PASI improvements in Phase 2a in patients with …
Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025
GlobeNewswire
·
May 9, 2025
Oral dual-targeted ABCB4/BSEP positive functional modulator (PFM) improved cholestatic and cholangitis markers in orthogonal models of hepatobiliary disease Data reinforce the potential of this differentiated mechanism of action (MOA) to address the core …
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 9, 2025
Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03 Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated liver fibrosis; currently reviewing data and on track to …